文献速递肿瘤 PET/CT

头颈部鳞状细胞癌治疗后无症状患者系统随访中使用18F-FDG PET/CT的3年总生存获益:一项多中心研究

3-year overall survival benefit of systematic follow-up with 18F-FDG PET/CT in asymptomatic patients treated for head and neck squamous cell carcinoma: a multicenter study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-02-26

这项多中心病例对照研究纳入2017年1月至2020年12月法国两个地区经组织学确诊并接受根治性治疗、影像学完全缓解的成人头颈部鳞状细胞癌患者697例,比较常规随访(508例)与常规随访联合每年系统18F-FDG PET/CT(189例)的3年总生存。Cox回归显示系统PET/CT有保护作用(OR=0.56,95%CI:0.397-0.795,p=0.001),PET/CT组3年总生存优于常规随访组(83.5±2.8% vs 73.4±2.1%,p=0.008)。

要点

  • 系统年度18F-FDG PET/CT组3年总生存83.5±2.8%,优于常规随访组73.4±2.1%(p=0.008)。
  • III/IV期患者中PET/CT组(n=124)3年总生存79.9±3.7%,优于常规随访组(n=312)71.5±2.7%(p=0.045)。
  • I/II期患者中PET/CT组3年总生存90.5±3.7%,优于常规随访组76.3±3.2%(p=0.047)。

核心结论

  • 在这项多中心研究中,使用18F-FDG PET/CT替代年度胸部CT作为头颈部鳞状细胞癌随访方式与3年生存获益相关。

研究设计与样本

  • 多中心病例对照研究,患者来自法国两个不同地区的两个医疗区域。
  • 纳入2017年1月至2020年12月间经组织学确诊并接受根治性治疗、影像学完全缓解的成人头颈部鳞状细胞癌患者。
  • 共纳入697例患者(男性534例[77%],中位年龄[IQR]62[57-69]岁),其中508例接受常规随访,189例接受常规随访联合每年系统18F-FDG PET/CT。
  • 主要终点为3年总生存,采用log-rank检验比较两组3年总生存率,采用Cox回归模型评估增加18F-FDG PET/CT对生存结局的影响。

主要发现

  • Cox回归分析显示系统18F-FDG PET/CT具有保护作用(OR=0.56,95%CI:0.397-0.795,p=0.001)。
  • PET/CT组3年总生存为83.5±2.8%,优于常规随访组的73.4±2.1%(p=0.008)。
  • 按分期分析,III/IV期患者中PET/CT组(n=124)3年总生存为79.9±3.7%,优于常规随访组(n=312)的71.5±2.7%(p=0.045)。
  • I/II期患者中PET/CT组3年总生存为90.5±3.7%,优于常规随访组的76.3±3.2%(p=0.047)。

临床怎么用

  • 作者结论指出,在头颈部鳞状细胞癌随访中使用18F-FDG PET/CT替代年度胸部CT与3年生存获益相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients diagnosed with head and neck squamous cell carcinoma (HNSCC) face a significant risk of locoregional recurrence within the first two years after treatment. While early detection of recurrence could potentially improve patient outcomes, the impact of such detection on survival remains uncertain. The aim was to assess the potential benefit of a systematic post-treatment follow-up strategy using 18 F-FDG PET/CT imaging on overall survival. METHODS: In this multicenter case-control study, patients were treated in two health areas from two different regions in France. All adults diagnosed with histologically confirmed HNSCC and treated between January 2017 and December 2020 with curative intent, with a complete response on imaging were included in the study. Primary endpoint was 3-year overall survival. The log-rank test was used to compare 3-year OS rates between the CFU (conventional follow-up) and PET/CT groups. A Cox regression model was used to assess the effect of the addition of 18 F-FDG PET/CT on survival outcomes. RESULTS: A total of 697 patients were included (534 males [77%], median age[IQR] 62[57-69] years); 508 patients had CFU and 189 patients had CFU + systematic annual 18 F-FDG PET/CT. Cox regression analysis showed a protective effect (OR = 0.56, 95%CI:0.397-0.795, p = 0.001) of systematic 18 F-FDG PET/CT. The 3-year OS in the PET/CT group was better than in the CFU group (83.5 ± 2.8% vs. 73.4 ± 2.1%, p = 0.008). The analysis based on stage showed a significantly better 3-year OS for advanced stage III/IV in the PET/CT group (n = 124) than in the CFU group (n = 312)(79.9 ± 3.7% vs. 71.5 ± 2.7%, p = 0.045) as well as for early stage I/II (90.5 ± 3.7% vs. 76.3 ± 3.2%, p = 0.047). CONCLUSION: In this multicenter study, the use of 18 F-FDG PET/CT as an alternative to annual chest CT in the follow-up of head and neck squamous cell carcinoma (HNSCC) is associated to a survival benefit at 3 years. CLINICAL TRIAL NUMBER: Not applicable (retrospective study).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mahéo C, Abgral R, Clément C, et al. 3-year overall survival benefit of systematic follow-up with 18F-FDG PET/CT in asymptomatic patients treated for head and neck squamous cell carcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40000460. doi:10.1007/s00259-025-07147-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。